InMed Pharmaceuticals Inc (INM)

[Matilda1]

I found this on the CSE monthly report for Inmed:

“The Company entered into a Consulting Agreement with Josh Blacher a non-related person, to provide services for Corporate Development and Investor Relations.”

This is what I found on him: (could be wrong though... might be just a guy they pulled off the street for advice ;)

Mr. Blacher joins Therapix with ten years of experience in senior financial and business development related positions at publicly-traded biotechnology and pharmaceutical companies, as well as 14 years in capital markets in the United States. Prior to joining Therapix, Mr. Blacher served as Chief Financial Officer at Galmed Pharmaceuticals (GLMD). Previously, Mr. Blacher also held senior positions in licensing and investing at Teva Pharmaceuticals, portfolio management at Deutsche Asset Management and equity research at Morgan Stanley, as well as in mergers & acquisitions at Lehman Brothers. Mr. Blacher holds an MBA in Finance from Columbia Business School.

"Now that Therapix has completed its U.S. IPO and NASDAQ listing, and initiated additional clinical trials, it is clear that we will need someone of Josh's caliber to help us develop and bring awareness of our growth strategy to the U.S. capital markets, as well as monetize our assets globally. We're confident that Josh's broad-based experience and track record will help us accomplish our objectives," commented Dr. Elran Haber, Therapix's Chief Executive Officer and Dr. Ascher Shmulewitz, the Company's Executive Chairman. Drs. Haber and Shmulewitz continued, "We're delighted to welcome Josh to the company."